Kristen K Ade1, Yehong Wan1, Harold C Hamann1, Justin K O'Hare1, Weirui Guo2, Anna Quian3, Sunil Kumar4, Srishti Bhagat1, Ramona M Rodriguiz4, William C Wetsel4, P Jeffrey Conn5, Kafui Dzirasa4, Kimberly M Huber2, Nicole Calakos6. 1. Departments of Neurology, Duke University Medical Center, Durham, North Carolina; Neurobiology, Duke University Medical Center, Durham, North Carolina. 2. Department of Neuroscience, University of Texas Southwestern Medical Center, Dallas, Texas. 3. Departments of Neurology, Duke University Medical Center, Durham, North Carolina. 4. Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, North Carolina. 5. Department of Neuroscience, University of Texas Southwestern Medical Center, Dallas, Texas; Department of Pharmacology, Vanderbilt University Medical Center, Nashville, Tennessee. 6. Departments of Neurology, Duke University Medical Center, Durham, North Carolina; Neurobiology, Duke University Medical Center, Durham, North Carolina. Electronic address: nicole.calakos@duke.edu.
Abstract
BACKGROUND: Development of treatments for obsessive-compulsive disorder (OCD) is hampered by a lack of mechanistic understanding about this prevalent neuropsychiatric condition. Although circuit changes such as elevated frontostriatal activity are linked to OCD, the underlying molecular signaling that drives OCD-related behaviors remains largely unknown. Here, we examine the significance of type 5 metabotropic glutamate receptors (mGluR5s) for behavioral and circuit abnormalities relevant to OCD. METHODS: Sapap3 knockout (KO) mice treated acutely with an mGluR5 antagonist were evaluated for OCD-relevant phenotypes of self-grooming, anxiety-like behaviors, and increased striatal activity. The role of mGluR5 in the striatal circuit abnormalities of Sapap3 KO mice was further explored using two-photon calcium imaging to monitor striatal output from the direct and indirect pathways. A contribution of constitutive signaling to increased striatal mGluR5 activity in Sapap3 KO mice was investigated using pharmacologic and biochemical approaches. Finally, sufficiency of mGluR5 to drive OCD-like behavior in wild-type mice was tested by potentiating mGluR5 with a positive allosteric modulator. RESULTS: Excessive mGluR5 signaling underlies OCD-like behaviors and striatal circuit abnormalities in Sapap3 KO mice. Accordingly, enhancing mGluR5 activity acutely recapitulates these behavioral phenotypes in wild-type mice. In Sapap3 KO mice, elevated mGluR5 signaling is associated with constitutively active receptors and increased and imbalanced striatal output that is acutely corrected by antagonizing striatal mGluR5. CONCLUSIONS: These findings demonstrate a causal role for increased mGluR5 signaling in driving striatal output abnormalities and behaviors with relevance to OCD and show the tractability of acute mGluR5 inhibition to remedy circuit and behavioral abnormalities.
BACKGROUND: Development of treatments for obsessive-compulsive disorder (OCD) is hampered by a lack of mechanistic understanding about this prevalent neuropsychiatric condition. Although circuit changes such as elevated frontostriatal activity are linked to OCD, the underlying molecular signaling that drives OCD-related behaviors remains largely unknown. Here, we examine the significance of type 5 metabotropic glutamate receptors (mGluR5s) for behavioral and circuit abnormalities relevant to OCD. METHODS:Sapap3 knockout (KO) mice treated acutely with an mGluR5 antagonist were evaluated for OCD-relevant phenotypes of self-grooming, anxiety-like behaviors, and increased striatal activity. The role of mGluR5 in the striatal circuit abnormalities of Sapap3 KO mice was further explored using two-photon calcium imaging to monitor striatal output from the direct and indirect pathways. A contribution of constitutive signaling to increased striatal mGluR5 activity in Sapap3 KO mice was investigated using pharmacologic and biochemical approaches. Finally, sufficiency of mGluR5 to drive OCD-like behavior in wild-type mice was tested by potentiating mGluR5 with a positive allosteric modulator. RESULTS: Excessive mGluR5 signaling underlies OCD-like behaviors and striatal circuit abnormalities in Sapap3 KO mice. Accordingly, enhancing mGluR5 activity acutely recapitulates these behavioral phenotypes in wild-type mice. In Sapap3 KO mice, elevated mGluR5 signaling is associated with constitutively active receptors and increased and imbalanced striatal output that is acutely corrected by antagonizing striatal mGluR5. CONCLUSIONS: These findings demonstrate a causal role for increased mGluR5 signaling in driving striatal output abnormalities and behaviors with relevance to OCD and show the tractability of acute mGluR5 inhibition to remedy circuit and behavioral abnormalities.
Authors: Alexxai V Kravitz; Benjamin S Freeze; Philip R L Parker; Kenneth Kay; Myo T Thwin; Karl Deisseroth; Anatol C Kreitzer Journal: Nature Date: 2010-07-07 Impact factor: 49.962
Authors: S Züchner; J R Wendland; A E Ashley-Koch; A L Collins; K N Tran-Viet; K Quinn; K C Timpano; M L Cuccaro; M A Pericak-Vance; D C Steffens; K R Krishnan; G Feng; D L Murphy Journal: Mol Psychiatry Date: 2009-01 Impact factor: 15.992
Authors: S E Stewart; D Yu; J M Scharf; B M Neale; J A Fagerness; C A Mathews; P D Arnold; P D Evans; E R Gamazon; L K Davis; L Osiecki; L McGrath; S Haddad; J Crane; D Hezel; C Illman; C Mayerfeld; A Konkashbaev; C Liu; A Pluzhnikov; A Tikhomirov; C K Edlund; S L Rauch; R Moessner; P Falkai; W Maier; S Ruhrmann; H-J Grabe; L Lennertz; M Wagner; L Bellodi; M C Cavallini; M A Richter; E H Cook; J L Kennedy; D Rosenberg; D J Stein; S M J Hemmings; C Lochner; A Azzam; D A Chavira; E Fournier; H Garrido; B Sheppard; P Umaña; D L Murphy; J R Wendland; J Veenstra-VanderWeele; D Denys; R Blom; D Deforce; F Van Nieuwerburgh; H G M Westenberg; S Walitza; K Egberts; T Renner; E C Miguel; C Cappi; A G Hounie; M Conceição do Rosário; A S Sampaio; H Vallada; H Nicolini; N Lanzagorta; B Camarena; R Delorme; M Leboyer; C N Pato; M T Pato; E Voyiaziakis; P Heutink; D C Cath; D Posthuma; J H Smit; J Samuels; O J Bienvenu; B Cullen; A J Fyer; M A Grados; B D Greenberg; J T McCracken; M A Riddle; Y Wang; V Coric; J F Leckman; M Bloch; C Pittenger; V Eapen; D W Black; R A Ophoff; E Strengman; D Cusi; M Turiel; F Frau; F Macciardi; J R Gibbs; M R Cookson; A Singleton; J Hardy; A T Crenshaw; M A Parkin; D B Mirel; D V Conti; S Purcell; G Nestadt; G L Hanna; M A Jenike; J A Knowles; N Cox; D L Pauls Journal: Mol Psychiatry Date: 2012-08-14 Impact factor: 15.992
Authors: Stefania Bellini; Kelsey E Fleming; Modhurika De; John P McCauley; Maurice A Petroccione; Lianna Y D'Brant; Artem Tkachenko; SoYoung Kwon; Lindsey A Jones; Annalisa Scimemi Journal: J Neurosci Date: 2017-12-11 Impact factor: 6.167
Authors: Cameron W Morris; Darryl S Watkins; Asma B Salek; Michael C Edler; Anthony J Baucum Journal: Mol Cell Neurosci Date: 2018-06-14 Impact factor: 4.314
Authors: Christian R Marks; Brian C Shonesy; Xiaohan Wang; Jason R Stephenson; Colleen M Niswender; Roger J Colbran Journal: Mol Pharmacol Date: 2018-10-03 Impact factor: 4.436
Authors: Brian C Shonesy; Walker P Parrish; Hala K Haddad; Jason R Stephenson; Rita Báldi; Rebecca J Bluett; Christian R Marks; Samuel W Centanni; Oakleigh M Folkes; Keeley Spiess; Shana M Augustin; Ken Mackie; David M Lovinger; Danny G Winder; Sachin Patel; Roger J Colbran Journal: Biol Psychiatry Date: 2017-12-28 Impact factor: 13.382
Authors: Elizabeth E Manning; Alexandre Y Dombrovski; Mary M Torregrossa; Susanne E Ahmari Journal: Neuropsychopharmacology Date: 2018-12-26 Impact factor: 7.853
Authors: Lotfi C Hadjas; Michael M Schartner; Jennifer Cand; Meaghan C Creed; Vincent Pascoli; Christian Lüscher; Linda D Simmler Journal: Neuropsychopharmacology Date: 2020-06-25 Impact factor: 7.853
Authors: Conor H Murray; Daniel T Christian; Mike Milovanovic; Jessica A Loweth; Eun-Kyung Hwang; Aaron J Caccamise; Jonathan R Funke; Marina E Wolf Journal: Neuropharmacology Date: 2021-01-12 Impact factor: 5.250